Advancing oncology and immunology through AI innovation
Strategic Pharmaceutical Innovation Partnership
Our partnership with Bristol Myers Squibb represents a transformative collaboration in oncology and immunology, leveraging AI to accelerate drug discovery, optimize clinical trials, and improve patient outcomes in cancer care and immune-mediated diseases.
AI-powered molecular design and target identification for novel therapeutics in oncology and immunology.
Advanced patient stratification and trial optimization using AI-driven biomarker discovery and analysis.
Personalized treatment recommendations and real-time monitoring for cancer and immune-mediated diseases.
AI models identified 15+ new therapeutic targets in immuno-oncology
40% reduction in patient recruitment time using AI-powered matching
Machine learning identified predictive biomarkers for treatment response
3 AI-assisted drug candidates received FDA Fast Track designation
AI-driven optimization of CAR-T cell therapy manufacturing and patient selection for improved efficacy and reduced toxicity in hematologic malignancies.
Machine learning models for identifying novel biomarkers predictive of checkpoint inhibitor response across multiple tumor types.
AI-powered screening of existing pharmaceuticals for new oncology indications, accelerating time-to-market for life-saving treatments.
Population pharmacokinetic modeling using AI to optimize dosing regimens for individual patients based on genomic and clinical factors.
AI-identified biomarker combination improved patient selection for checkpoint inhibitor therapy, resulting in 85% response rate compared to 45% with standard selection criteria.
Machine learning models reduced lead compound optimization time from 18 months to 6 months, advancing a novel immunotherapy into Phase I trials 2 years ahead of schedule.
AI-powered patient matching platform reduced trial enrollment time by 60% and improved patient diversity, leading to more representative and faster clinical studies.
VP, Digital Health & AI - BMS
Leading AI integration across BMS R&D pipeline
Chief AI Officer - SynThera
Overseeing pharmaceutical AI partnerships
AI-optimized immunotherapy combination
First AI-assisted BLA filing
Extension to autoimmune diseases
Our partnership with Bristol Myers Squibb is revolutionizing oncology through AI-powered innovation